Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Equity Average (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Equity Average for 10 consecutive years, with $12.0 million as the latest value for Q3 2025.

  • Quarterly Equity Average rose 169.23% to $12.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Sep 2025, up 169.23% year-over-year, with the annual reading at $8.5 million for FY2024, 43.78% down from the prior year.
  • Equity Average hit $12.0 million in Q3 2025 for Aptevo Therapeutics, up from $2.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $20.6 million in Q1 2023 to a low of -$2.3 million in Q1 2022.
  • Historically, Equity Average has averaged $10.1 million across 5 years, with a median of $10.6 million in 2021.
  • Biggest five-year swings in Equity Average: tumbled 117.23% in 2022 and later soared 983.25% in 2023.
  • Year by year, Equity Average stood at $4.3 million in 2021, then soared by 296.52% to $16.9 million in 2022, then fell by 20.15% to $13.5 million in 2023, then crashed by 65.94% to $4.6 million in 2024, then soared by 160.66% to $12.0 million in 2025.
  • Business Quant data shows Equity Average for APVO at $12.0 million in Q3 2025, $2.5 million in Q2 2025, and $1.6 million in Q1 2025.